BTIG Names Guardant Health Top Healthcare Pick, Raises Price Target to $195

Investment firm BTIG has named Guardant Health (NASDAQ: GH) its top pick in the healthcare sector, raising its price target on the diagnostics company following a strong second-quarter earnings report and an upgraded financial outlook. The firm highlighted Guardant's leadership in the liquid biopsy market and a series of potential growth catalysts on the horizon.

Analyst Upgrade on Strong Results

BTIG reiterated its Buy rating for Guardant Health and increased its 12-month price target to $195, up from a previous $190. The revision was driven by the company's second-quarter performance, where it reported revenues of $335 million, representing 44% growth, and subsequently raised its full-year guidance.

A key performance indicator cited in the report was a 63% year-over-year increase in core oncology test volume. In its note to clients, BTIG described Guardant as a "must own" market leader in specialty diagnostics, emphasizing that its key opportunities in oncology, cancer screening, and minimal residual disease (MRD) testing remain in the early stages of market adoption.

Key Growth Catalysts

BTIG identified several upcoming milestones that could provide further upside for the stock. These potential catalysts are central to the firm's positive thesis for investors.

Ad

Key developments include:

• Expanded CMS Coverage: The potential for the Centers for Medicare & Medicaid Services (CMS) to provide coverage for Guardant's Reveal MRD test for breast cancer, immunotherapy, and chemotherapy monitoring.
• New Product Launches: The company is on track to launch its Reveal Ultra MRD test in the second half of 2026 and its recently FDA-cleared G360 Smart Liquid test in the first half of 2027.
• ADLT Status: For the G360 test, Guardant is targeting a higher price point by obtaining Advanced Diagnostic Laboratory Test (ADLT) status.

Market Position and Context

Guardant Health is a pioneer in the field of liquid biopsies, which use blood tests to detect cancer and guide treatment. BTIG noted that the company is well-positioned through its large and comprehensive clinical trials, including its 20,000-patient ECLIPSE study for the early detection of colorectal cancer.

The positive sentiment from BTIG follows similar actions from other Wall Street firms. Both Stifel and TD Cowen also raised their price targets on Guardant Health in response to its strong quarterly results and outlook.